Personalis, Inc. 10-Q Summary
Business Context and Reporting Period
Personalis, Inc. is a cancer genomics company providing sequencing and data-analysis services for cancer-therapy development and population-sequencing initiatives. The company operates as one reportable segment. Population sequencing, primarily through the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP), remained the largest revenue source. The filing covers the three months ended March 31, 2021, compared with the three months ended March 31, 2020.
Financial Results and Key Metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $20.9 million | $19.2 million | +9% |
| Gross profit | $7.4 million | $4.0 million | +86% |
| Gross margin | 35.6% | 21.0% | +14.6 percentage points |
| Loss from operations | $(12.5) million | $(9.6) million | Loss increased |
| Operating margin | (59.8%) | (50.2%) | Declined |
| Net loss | $(12.4) million | $(9.1) million | Loss increased |
| Net loss per share | $(0.29) | $(0.29) | Flat |
| Net cash used in operations | $(11.7) million | $(8.6) million | Higher use |
Research and development expense increased 49% to $9.5 million, while selling, general and administrative expense increased 43% to $10.4 million. Total costs and expenses rose 16% to $33.4 million. Interest income declined 81% to $0.1 million because of lower investment yields, despite higher cash and investment balances.
Cash and cash equivalents were $137.1 million at March 31, 2021, and short-term investments were $216.3 million, for total cash and investments of $353.4 million. Working capital was $334.1 million. The company reported no debt, total liabilities of $47.1 million, and total stockholders’ equity of $348.4 million. Operating lease liabilities totaled $10.6 million, including $8.2 million classified as long term.
Material Changes Versus the Prior Comparable Period
- Revenue from VA MVP decreased 10% to $13.2 million, primarily because fewer samples were processed.
- Revenue from all other customers increased 74% to $7.7 million. NeXT Platform revenue exceeded $4 million versus less than $0.5 million in Q1 2020.
- VA MVP represented 63% of revenue, down from 77% in Q1 2020. Pfizer represented 12% of revenue in Q1 2021.
- Costs of revenues declined 11% to $13.5 million, reflecting favorable customer mix and improved laboratory processing efficiency.
- Gross margin improved materially to 35.6%, but operating losses widened as the company increased investment in product development, automation, commercial capabilities, headcount, and infrastructure.
- The company completed a January 2021 follow-on equity offering and received approximately $162.3 million of net proceeds, including the underwriters’ overallotment exercise. Shares outstanding increased to 43.8 million at March 31, 2021 from 39.1 million at December 31, 2020.
- Stock-based compensation increased to $3.1 million from $1.2 million. A modification of options held by two non-employee directors produced $1.2 million of incremental compensation cost, of which $0.6 million was recognized in the quarter.
Guidance, Outlook, Commentary, Risks, and Unusual Items
Management expects continued net losses for the foreseeable future and plans to increase research and development, selling and marketing, infrastructure, and capital expenditures. The filing does not provide formal revenue or earnings guidance. Management stated that cash and short-term investments, together with expected operating cash flows, should fund near-term requirements for at least the next 12 months, although actual cash usage could be higher than anticipated.
Contracted but unrecognized revenue was $30.3 million at March 31, 2021, with the substantial majority expected to be recognized within the next two quarters. The company reported approximately $18.2 million of customer deposits, including $16.3 million from one customer, which could require repayment if services are canceled or reduced.
The VA MVP contract expires in August 2021 and does not include a renewal option. The current task order extends through August 2021. Future awards are uncertain and may be subject to competitive bidding, funding availability, sample volumes, and government priorities.
COVID-19 continued to affect laboratory access, research and development productivity, customer sample collection, supplier availability, and sales activity. The company also relies on limited or sole-source suppliers, including Illumina for sequencers and related reagents. Other significant risks include continued losses, customer concentration, regulatory requirements for laboratory-developed tests and international operations, data privacy and cybersecurity exposure, intellectual-property disputes, execution risks from scaling infrastructure, and potential dilution or financing constraints.
As of March 31, 2021, the company reported no material legal proceedings. Management concluded that disclosure controls and procedures were effective, and reported no changes in internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Whether the VA MVP contract is renewed or replaced after its August 2021 expiration, and the value and timing of future task orders.
- Whether the $30.3 million of contracted, unrecognized revenue converts to revenue as expected during the following two quarters.
- Whether growth in NeXT Platform and other pharmaceutical-customer revenue can offset continued dependence on VA MVP.
- Whether improved gross margins persist as laboratory volume and customer mix change.
- The pace of operating cash burn, capital expenditures, and any need for additional equity or debt financing.
- Potential repayment obligations associated with the $18.2 million of customer deposits, particularly the $16.3 million deposit from one customer.
- Effects of COVID-19, supply-chain constraints, Illumina contract renewals, and regulatory developments on laboratory operations.
- The impact of stock-based compensation and additional equity issuance on future dilution.